Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 12/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14095901 | 0.82 | HDAC3 (0.38) | HTR5AHDAC3HDAC1HDAC2CREBBP | |
| SCHEMBL18388633 | 0.82 | HTR5A (0.43) | HTR5AHDAC3HDAC1HDAC2 | |
| SCHEMBL2666124 | 0.80 | MEN1 (0.40) | HTR5ANOS2CREBBPBRD4MEN1 | |
| SCHEMBL727320 | 0.79 | HTR2A (0.43) | HTR5AHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL19114614 | 0.78 | HDAC3 (0.36) | HTR5AHDAC3HDAC1HDAC2CREBBP | |
| SCHEMBL12808124 | 0.77 | NOS2 (0.38) | HTR5ANOS2CREBBPBRD4MEN1 | |
| SCHEMBL14304542 | 0.77 | HTR2A (0.46) | HTR5AHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL21898300 | 0.76 | HTR5A (0.41) | HTR5AHDAC3HDAC1HDAC2NOS2 | |
| SCHEMBL19308761 | 0.76 | HDAC3 (0.35) | HTR5AHDAC3HDAC1HDAC2 | |
| SCHEMBL8291311 | 0.74 | HTR5A (0.35) | HTR5ANOS2CREBBPBRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR5A 1095/4885HDAC3 1000/4885HDAC1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.